GO
| HSI1 | 25,818.93 | +44.79 | 92.52B |
| HSCEI1 | 8,915.12 | +1.29 | 34.27B |
| Back Zoom + Zoom - Block Traded | |
|
CKLIFE SCIENCES: Positive Results Obtained from Interim Analysis of Halneuron Phase 2b Study
2025-12-23 08:31:18 CKLIFE SCIENCES (00775.HK)'s biopharmaceutical company, Dogwood Therapeutics, Inc. (DWTX.US), announced positive results from an interim analysis of the ongoing Phase 2b chemotherapy-induced neuropathic pain (CINP) study of the non-opioid NaV 1.7 inhibitor, Halneuron, according to CKLIFE SCIENCES' announcement. The independent statistical review committee concluded that Halneuron treated patients are demonstrating separation from placebo treated patients in terms of pain improvement. Based on the current Phase 2b trial enrollment pace and the interim assessment results, Dogwood expected to have top-line results available during 3Q26. The current study is projected to provide statistical power of approx. 80-85% to detect a Halneuron treatment difference. ~ AASTOCKS Financial News Website: www.aastocks.com | |